CAMBRIDGE, England, October 31, 2022 — Eagle Genomics, a pioneering TechBio platform firm that applies network science1 to biology, today announced the first closing of its scale-up investment round of USD 20 million. The funding will support the continued development of the TM 2 platform and additional growth into global markets and client impact.
The financing is being led by abrdn plc, with previous investors Environmental Technologies Fund and a consortium of investors led by Granpool Innovative Investments continuing to participate. The current investment round will be extended to allow for further participation of up to USD 10 million.
Eagle Genomics is the premier TechBio firm pioneering in the application of network science to biological discovery and innovation in the Food and Nutrition, AgBio, Beauty and Personal Care, and Biopharma industries. The e[datascientist] platform enables corporate clients to track digital journeys in data, enabling revolutionary breakthroughs, leveraging cutting-edge scientific research in silico, and enabling specific product claims.
Eagle Genomics’ objective is to advance the Bioeconomy through digital reinvention of life sciences research and development. The firm is increasingly focused on assisting its clients in addressing ‘One Health’ concerns in order to generate more sustainable and impact-oriented innovation and product outcomes.
The concept of ‘One Health’ recognizes that human, animal, and environmental health are intrinsically intertwined. Using technology to solve challenges in one area may inspire and enable progress in another.
Eagle Genomics CEO Anthony Finbow stated:
“We are the preeminent platform company driving the Bioeconomy with next-generation graph technology and network science. We want to assist our enterprise customers in their efforts to create more sustainable and impact-oriented innovation outcomes. The present scale-up investment will allow us to advance the Bioeconomy through digital scientific innovation.”
More about the startup:
Eagle Genomics is advancing the Bioeconomy via the digital reinvention of life sciences research and development by inventing at the intersection of biology, data sciences, and bioinformatics. The company’s award-winning AI-augmented knowledge discovery platform, e[datascientist]TM, enables scientists to exploit the multi-dimensional data in minutes rather than months, allowing enterprises to undertake science-led innovation for next-generation products.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
